{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:59:46Z","timestamp":1789736386135,"version":"4.0.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>In typical patients with multiple system atrophy with predominant parkinsonism (MSA-P) levodopa is ineffective. However, there are some of these patients who respond well to levodopa treatment. Levodopa efficacy in MSA-P patients is thought to be related to the degree of putaminal damage, but the pathological causation between the putaminal involvement and levodopa efficacy has not been established in detail.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to evaluate the neuropathological features of the nigrostriatal dopaminergic system in a \u201clevodopa-responsive\u201d MSA-P patient in comparison with \u201clevodopa-unresponsive\u201d conventional MSA-P patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Clinicopathological findings were assessed in a 53-year-old Japanese man with MSA who presented with asymmetric parkinsonism, levodopa response, and later wearing-off phenomenon. During autopsy, the nigrostriatal pathology of presynaptic and postsynaptic dopaminergic receptor density and \u03b1-synuclein status were investigated. The other two patients with MSA-P were examined using the same pathological protocol.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Four years after the onset, the patient died of sudden cardiopulmonary arrest. On autopsy, numerous \u03b1-synuclein-positive glial cytoplasmic inclusions in the basal ganglia, pons, and cerebellum were identified. The number of neurons in the putamen and immunoreactivity for dopamine receptors were well-preserved. In contrast, significant neuronal loss and decreased dopamine receptor immunoreactivity in the putamen were observed in the \u201clevodopa-unresponsive\u201d MSA-P control patients. These putaminal pathology results were consistent with the findings of premortem magnetic resonance imaging (MRI). All three patients similarly exhibited severe neuronal loss in the substantia nigra and decreased immunoreactivity for dopamine transporter.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Levodopa responsiveness in patients with MSA-P may be corroborated by the normal putamen on MRI and the preserved postsynaptic nigrostriatal dopaminergic system on pathological examination. The results presented in this study may provide a rationale for continuation of levodopa treatment in patients diagnosed with MSA-P.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1293732","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T10:23:02Z","timestamp":1699957382000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Neuropathological features of levodopa-responsive parkinsonism in multiple system atrophy: an autopsy case report and comparative neuropathological study"],"prefix":"10.3389","volume":"14","author":[{"given":"Mitsuyoshi","family":"Tamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Kitayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Suichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumoto","family":"Shibuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakurako","family":"Harada-Kagitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.tins.2011.08.003","article-title":"Multiple system atrophy: a clinical and neuropathological perspective","volume":"34","author":"Ubhi","year":"2011","journal-title":"Trends Neurosci"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"a009258","DOI":"10.1101\/cshperspect.a009258","article-title":"Parkinson's disease and parkinsonism: neuropathology","volume":"2","author":"Dickson","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1212\/WNL.0000000000001807","article-title":"When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients","volume":"85","author":"Koga","year":"2015","journal-title":"Neurology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1136\/jnnp.68.4.434","article-title":"What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease?","volume":"68","author":"Wenning","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/jnnp.55.11.1009","article-title":"The dopaminergic response in multiple system atrophy","volume":"55","author":"Hughes","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1093\/brain\/awh303","article-title":"The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations","volume":"127","author":"Ozawa","year":"2004","journal-title":"Brain"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/mds.870120203","article-title":"Multiple system atrophy: a review of 203 pathologically proven cases","volume":"12","author":"Wenning","year":"1997","journal-title":"Mov Disord"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","article-title":"Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry","volume":"112","author":"Braak","year":"2006","journal-title":"Acta Neuropathol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","article-title":"Second consensus statement on the diagnosis of multiple system atrophy","volume":"71","author":"Gilman","year":"2008","journal-title":"Neurology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/brain\/awab017","article-title":"Identification of multiple system atrophy mimicking Parkinson's disease or progressive supranuclear palsy","volume":"144","author":"Miki","year":"2011","journal-title":"Brain"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2169\/internalmedicine.4836-20","article-title":"Effectiveness of levodopa in patients with multiple system atrophy and associated Clinicopathological features","volume":"60","author":"Ishida","year":"2021","journal-title":"Intern Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S1474-4422(12)70327-7","article-title":"The natural history of multiple system atrophy: a prospective European cohort study","volume":"12","author":"Wenning","year":"2013","journal-title":"Lancet Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/S1474-4422(15)00058-7","article-title":"Natural history of multiple system atrophy in the USA: a prospective cohort study","volume":"14","author":"Low","year":"2015","journal-title":"Lancet Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"033","DOI":"10.1055\/s-2001-13117","article-title":"Multiple system atrophy","volume":"21","author":"Wenning","year":"2001","journal-title":"Semin Neurol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1212\/wnl.41.11.1723","article-title":"Challenge tests to predict the dopaminergic response in untreated Parkinson's disease","volume":"41","author":"Hughes","year":"1991","journal-title":"Neurology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/mds.870090206","article-title":"\"minimal change\" multiple system atrophy","volume":"9","author":"Wenning","year":"1994","journal-title":"Mov Disord"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/mds.10190","article-title":"Presynaptic parkinsonism in multiple system atrophy mimicking Parkinson's disease: a clinicopathological case study","volume":"17","author":"Berciano","year":"2002","journal-title":"Mov Disord"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1093\/brain\/120.12.2187","article-title":"Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease","volume":"120","author":"Antonini","year":"1997","journal-title":"Brain"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"588","DOI":"10.2967\/jnumed.109.070144","article-title":"Combined striatal binding and cerebral influx analysis of dynamic 11C-raclopride PET improves early differentiation between multiple-system atrophy and Parkinson disease","volume":"51","author":"Van Laere","year":"2010","journal-title":"J Nucl Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"116627","DOI":"10.1016\/j.jns.2019.116627","article-title":"Differences in cerebellar perfusion between Parkinson's disease and multiple system atrophy","volume":"409","author":"Murakami","year":"2020","journal-title":"J Neurol Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1002\/mds.26052","article-title":"Neuropathology of multiple system atrophy: new thoughts about pathogenesis","volume":"29","author":"Jellinger","year":"2014","journal-title":"Mov Disord"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1293732\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T10:23:07Z","timestamp":1699957387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1293732\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":21,"alternative-id":["10.3389\/fneur.2023.1293732"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1293732","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,14]]},"article-number":"1293732"}}